Recent financial disclosures highlight varied biotech performance: Adaptive Biotechnologies reports a 36% Q2 revenue increase driven by minimal residual disease testing, Sophia Genetics grows revenues 16% expanding collaborations with AstraZeneca, and Bio-Techne posts 4% fiscal Q4 revenue gain while divesting Exosome Diagnostics to MDxHealth. Meanwhile, Yatiri Bio acquires NGeneBioAI to augment AI-powered proteomics. These movements underscore dynamic sector growth fueled by innovation and strategic alignments.